The DEA’s expedited administrative hearing, set to begin June 29, 2026, and conclude no later than July 15, 2026, represents the central driver of trader sentiment around full marijuana rescheduling from Schedule I to Schedule III. A final order issued April 23, 2026, already moved FDA-approved products and state-licensed medical marijuana to Schedule III, effective April 28, yet broader coverage including recreational use remains subject to the ongoing rulemaking. President Trump’s December 2025 executive order accelerated the process, prompting the DEA to withdraw prior proceedings and establish firm deadlines plus a new registration pathway for qualifying medical operators. Market pricing reflects uncertainty over potential litigation, hearing outcomes, and the timeline for any final rule, with traders monitoring procedural milestones and Senate or court developments that could extend or shorten resolution.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড$758,542 Vol.
Mar 31, 2026
June 30
1%
December 31
24%
$758,542 Vol.
June 30
$337,166 Vol.
1%
December 31
$156,494 Vol.
24%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The DEA’s expedited administrative hearing, set to begin June 29, 2026, and conclude no later than July 15, 2026, represents the central driver of trader sentiment around full marijuana rescheduling from Schedule I to Schedule III. A final order issued April 23, 2026, already moved FDA-approved products and state-licensed medical marijuana to Schedule III, effective April 28, yet broader coverage including recreational use remains subject to the ongoing rulemaking. President Trump’s December 2025 executive order accelerated the process, prompting the DEA to withdraw prior proceedings and establish firm deadlines plus a new registration pathway for qualifying medical operators. Market pricing reflects uncertainty over potential litigation, hearing outcomes, and the timeline for any final rule, with traders monitoring procedural milestones and Senate or court developments that could extend or shorten resolution.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
মার্কেট ওপেন হয়েছে: Feb 7, 2026, 5:04 PM ET
ভলিউম
$758,542শেষ তারিখ
Mar 31, 2026মার্কেট ওপেন হয়েছে
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The DEA’s expedited administrative hearing, set to begin June 29, 2026, and conclude no later than July 15, 2026, represents the central driver of trader sentiment around full marijuana rescheduling from Schedule I to Schedule III. A final order issued April 23, 2026, already moved FDA-approved products and state-licensed medical marijuana to Schedule III, effective April 28, yet broader coverage including recreational use remains subject to the ongoing rulemaking. President Trump’s December 2025 executive order accelerated the process, prompting the DEA to withdraw prior proceedings and establish firm deadlines plus a new registration pathway for qualifying medical operators. Market pricing reflects uncertainty over potential litigation, hearing outcomes, and the timeline for any final rule, with traders monitoring procedural milestones and Senate or court developments that could extend or shorten resolution.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ভলিউম
$758,542শেষ তারিখ
Mar 31, 2026মার্কেট ওপেন হয়েছে
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...The DEA’s expedited administrative hearing, set to begin June 29, 2026, and conclude no later than July 15, 2026, represents the central driver of trader sentiment around full marijuana rescheduling from Schedule I to Schedule III. A final order issued April 23, 2026, already moved FDA-approved products and state-licensed medical marijuana to Schedule III, effective April 28, yet broader coverage including recreational use remains subject to the ongoing rulemaking. President Trump’s December 2025 executive order accelerated the process, prompting the DEA to withdraw prior proceedings and establish firm deadlines plus a new registration pathway for qualifying medical operators. Market pricing reflects uncertainty over potential litigation, hearing outcomes, and the timeline for any final rule, with traders monitoring procedural milestones and Senate or court developments that could extend or shorten resolution.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড
বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা